FIELD: pharmaceutical chemistry.
SUBSTANCE: inventions group relates to pharmaceutical chemistry and includes a pyrimidine derivative of formula (I), its stereoisomer or pharmaceutically acceptable salt, a pharmaceutical composition, an antitumor agent, an application and a method for treatment. Wherein in formula (I) R1 is a C1-C4 alkyl group optionally having a C1-C4 alkoxy group as a substituent, or a C3-C4 cycloalkyl group; R2 represents a hydrogen atom, a halogen atom, a C1-C6 alkyl group optionally substituted with 1 to 5 C1-C4 alkoxy groups or fluorine atoms, or a C1-C6 alkoxy group; R3 represents a hydrogen atom or a C1-C4 alkyl group optionally substituted with 1 to 5 fluorine atoms; R4 represents a hydrogen atom or a C1-C4 alkyl group; and R5 is a phenyl group optionally having 1-3 substituents selected from fluorine atoms and chlorine atoms.
EFFECT: compound of formula (I) which inhibits HER2 activity and is used to treat a tumor associated with HER2.
21 cl, 6 dwg, 5 tbl, 49 ex
| Title | Year | Author | Number |
|---|---|---|---|
| CHIMERIC ANTIGEN RECEPTORS TARGETING HER2 | 2016 |
|
RU2753695C2 |
| CONJUGATES OF BINDER AND ACTIVE SUBSTANCE (ADC) HAVING ENZYMATICALLY CLEAVABLE GROUPS | 2017 |
|
RU2761390C2 |
| ANTIBODY-DRUG CONJUGATES CONTAINING HERBOXYDIENE-BASED SPLICING MODULATOR, AND METHODS OF USE THEREOF | 2019 |
|
RU2820607C2 |
| ANTITUMOR COMPOUNDS | 2018 |
|
RU2773023C2 |
| INTRODUCTION OF CONSTRUCTED T CELLS FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM CANCER | 2017 |
|
RU2757308C2 |
| SITE-SPECIFIC HER2 ANTIBODY-DRUG CONJUGATES | 2016 |
|
RU2745565C2 |
| METHODS OF USING BISPECIFIC ANTIGEN-BINDING CONSTRUCT TARGETING HER2 FOR TREATING BILE DUCT CANCER | 2019 |
|
RU2819802C2 |
| HER-2-DIRECTED ANTIGEN-BINDING MOLECULES CONTAINING 4-1BBL | 2019 |
|
RU2815451C2 |
| IMMUNOCYTOKINES AND THEIR USE | 2021 |
|
RU2818371C1 |
| BISPECIFIC ANTIGEN-BINDING MOLECULES AND METHODS OF THEIR USE | 2019 |
|
RU2800779C2 |
